Moderna Prepares To Enter The RSV Vaccine Fray
Its mRNA-based RSV vaccine challenger has a more convenient administration than GSK and Pfizer’s frontrunners, but may not compete on durability of protection.
Its mRNA-based RSV vaccine challenger has a more convenient administration than GSK and Pfizer’s frontrunners, but may not compete on durability of protection.